What are the risk factors for venous thromboembolism (VTE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Risk Factors for Venous Thromboembolism

VTE results from a complex interplay between patient-related (usually permanent) and setting-related (usually temporary) risk factors, with the most critical being advanced age, active malignancy, major surgery/trauma, hospitalization, immobilization, prior VTE history, and inherited thrombophilias. 1

Patient-Related (Usually Permanent) Risk Factors

Demographic Factors

  • Age: Risk increases dramatically with age—before age 40, risk is approximately 1 in 10,000 persons per year, escalating to 1 in 100 persons per year after age 75 1
  • Male sex: Associated with higher VTE risk and increased recurrence rates 1

Genetic/Inherited Thrombophilias

The most common genetic predispositions include:

  • Factor V Leiden (FVL): Present in approximately 5.1% of non-Hispanic whites, 2.0% of Hispanic whites, and 1.2% of African Americans 2
  • **Prothrombin G20210A (Factor II c.*97G>A)**: Second most common genetic mutation 1
  • Deficiencies in natural anticoagulants: Antithrombin III, Protein C, and Protein S (account for 5-10% of thrombosis cases and have more quantifiable VTE association) 1

Critical caveat: Genetic factors are present in only 25% of screening populations without family history and up to 63% of familial cases. Approximately 50% of first-time VTE cases are unprovoked, meaning no clear risk factor is identified 1.

Medical Comorbidities

  • Obesity: Body mass index ≥35 kg/m² increases risk 3
  • Diabetes 4
  • Cardiac conditions: Heart failure, atrial fibrillation 4
  • Chronic respiratory failure 4

Prior VTE History

History of previous VTE is one of the strongest independent risk factors, with recurrence rates of approximately 20% within 5 years and 30% within 10 years after the first event 1. In cancer patients, 12-month cumulative recurrence reaches 20.7% compared to 6.8% in non-cancer patients 4.

Setting-Related (Usually Temporary) Risk Factors

Hospitalization and Critical Illness

  • Hospitalization alone: Increases VTE risk 8-fold 5
  • Critical illness: Strongly associated with VTE (up to 20% incidence in ICU patients) 6
  • Hospital or nursing home confinement: OR 8.0 (95% CI: 4.5-14.2) 7

Surgical and Trauma-Related

The strongest provoking factors include:

  • Major surgery: OR 21.7 (95% CI: 9.4-49.9) 8, 7
  • Major trauma: OR 12.7 (95% CI: 4.1-39.7) 7
  • Hip fracture and lower extremity fractures 8
  • Spinal cord injury with paralysis 8
  • Length of anesthesia 3

Immobilization

  • Prolonged immobilization: Includes bed rest, prolonged travel 1
  • Acute paresis/neurological disease with extremity paresis: OR 3.0 (95% CI: 1.3-7.4) 5, 7
  • Lower Barthel Index score (indicating reduced functional status) 6

Malignancy-Related Factors

Cancer increases VTE risk 4- to 7-fold, with the highest risk in:

  • Very high-risk cancers (risk score 2): Pancreatic and gastric adenocarcinoma 3, 8
  • High-risk cancers (risk score 1): Lung, hematological malignancies, brain tumors, gynecological, bladder, testicular 3, 4, 8
  • Metastatic disease: OR 19.8 for solid tumors with distant metastases 4

Chemotherapy-specific factors 3:

  • Chemotherapy increases risk through vessel wall damage, endothelial injury, decreased natural anticoagulants, and platelet activation
  • Antiangiogenic agents (bevacizumab, thalidomide, lenalidomide): 33% relative increase in VTE risk; overall incidence 11.9% (any-grade) and 6.3% (high-grade) 3
  • Thalidomide plus doxorubicin: VTE rates up to 34% in multiple myeloma 3

Additional cancer-related factors:

  • Central venous catheter or pacemaker: OR 5.6 (95% CI: 1.6-19.6) 7
  • Extrinsic vascular compression from bulky lymphadenopathy 4

Hematological Abnormalities

  • Prechemotherapy platelet count ≥350,000/µL (risk score 1) 3
  • Prechemotherapy leukocyte count >11,000/µL (risk score 1) 3, 6
  • Hemoglobin <10 g/dL or use of erythropoiesis-stimulating agents (risk score 1) 3, 4
  • Elevated D-dimer levels: OR 2.46 (95% CI: 1.37-4.40) 6, 9
  • Elevated C-reactive protein and fibrinogen 6
  • Thrombocytosis, tachycardia, fever 6

Infection

Acute infection is a critical and often underrecognized risk factor:

  • Increases VTE risk 3-fold within the first 3 months after infection 4
  • In cancer patients, infection is a major predictor of VTE hospitalization 4
  • This factor is notably absent from many widely used risk assessment models 5

Hormone-Related Factors

For women of reproductive age and postmenopausal women:

  • Combined oral contraceptives: 2- to 6-fold increase in VTE risk over baseline 8
    • Third-generation contraceptives (desogestrel, gestodene) carry higher risk than second-generation (levonorgestrel, norgestrel) 8
    • Hormone-releasing intrauterine devices and progesterone-only pills do NOT significantly increase VTE risk 8
  • Pregnancy and postpartum period 1
  • Estrogen replacement therapy 1
  • Tamoxifen and raloxifene treatment (in breast cancer patients) 1

Other Acquired Factors

  • Blood transfusions: Significant risk factor, especially in cancer patients 4
  • Superficial vein thrombosis: OR 4.3 (95% CI: 1.8-10.6) 7
  • Varicose veins: Risk diminishes with age (OR 4.2 at age 45 vs. 0.9 at age 75) 7
  • Invasive mechanical ventilation: OR 2.08 (95% CI: 1.46-2.96) 9
  • Central venous catheterization: OR 2.67 (95% CI: 1.67-4.28) 9

Risk Stratification for Ambulatory Cancer Patients

The Khorana score provides validated risk stratification 3:

  • Low risk (score 0): 0.3-0.5% VTE incidence
  • Intermediate risk (score 1-2): 2% VTE incidence
  • High risk (score ≥3): 6.7-7% VTE incidence

Important Clinical Pitfalls

  1. Approximately 50% of first-time VTE cases appear unprovoked, meaning no obvious risk factor is identified despite thorough evaluation 1

  2. Risk factors act synergistically: Most patients with VTE have multiple risk factors present simultaneously, including up to half of those with genetic predisposition 2

  3. Acute infection is frequently overlooked as a VTE risk factor and is not included in most widely used risk assessment models 5

  4. Not all inherited thrombophilias carry equal risk: Factor V Leiden and prothrombin mutations were NOT associated with increased VTE risk in cancer patients receiving chemotherapy 4

  5. Liver disease paradoxically reduces VTE risk: OR 0.1 (95% CI: 0.0-0.7) 7

References

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.